MxA-Guided Antiviral Treatment in Respiratory Viral Infections

Last updated: March 2, 2026
Sponsor: Capital Medical University
Overall Status: Completed

Phase

N/A

Condition

Influenza

Treatment

MxA feedback

Follow-up at Day 30

MxA tests

Clinical Study ID

NCT06668025
2023-I2M-C&T-B-119
  • Ages > 18
  • All Genders

Study Summary

This pilot randomized controlled trial (RCT) will investigate the clinical impact of Myxovirus Resistance Protein A (MxA)-guided antiviral treatment versus standard treatment in patients with respiratory viral infections.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ≥ 18 years old

  • With a primary diagnosis of influenza or COVID-19 infection, diagnosed by a rapidantigen test or RT-PCR

  • Duration of infection ≤14 days for non-severe patients and < 28 days for patientswith severe infections

  • Currently receiving or planned to receive antiviral treatment, with the attendingphysician yet to decide on the discontinuation of the antiviral treatment

Exclusion

Exclusion Criteria:

  • Current endotracheal intubation and mechanical ventilation

  • Current vasopressor use

  • Known immunosuppression

  • Received interferon therapy within 30 days before screening

  • Systemic inflammatory responses within 30 days prior to screening, such as cerebralinfarction, myocardial infarction, or surgery

  • Received vaccine in the past 30 days

  • Active tuberculosis

  • With contraindications for antiviral treatment

  • Unable to obtain eligible samples

  • Co-infected with influenza and COVID-19

Study Design

Total Participants: 86
Treatment Group(s): 3
Primary Treatment: MxA feedback
Phase:
Study Start date:
December 12, 2024
Estimated Completion Date:
February 12, 2026

Study Description

Effective antiviral treatment would shorten the time to symptom resolution, accelerate the cessation of viral shedding, and improve the prognosis of respiratory viral infections. However, the optimal timing for antiviral treatment remains undetermined, and the current lack of objective biomarkers for respiratory viral infections often leads to either prolonged or insufficient antiviral treatment. Thus, there is a need for strategies that incorporate novel diagnostics to guide antiviral treatment and provide more individualized therapy.

Myxovirus resistance protein A (MxA), a novel marker of viral infection, may hold potential in guiding antiviral therapy. In this pilot randomized controlled clinical study, we aim to evaluate whether MxA-guided antiviral treatment, as compared to standard care, can reduce the recurrence rate of respiratory viral infections and improve clinical outcomes

Connect with a study center

  • China-Japan Friendship Hospital

    Beijing, Beijing 100020
    China

    Site Not Available

  • China-Japan Friendship hospital

    Beijing, Beijing Municipality 100029
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.